Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Truist Financial Reaffirms Their Buy Rating on AbCellera Biologics (ABCL)

Tipranks - Tipranks - Fri Aug 15, 2025

In a report released today, Srikripa Devarakonda from Truist Financial reiterated a Buy rating on AbCellera Biologics, with a price target of $10.00. The company’s shares closed yesterday at $4.58.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

According to TipRanks, Devarakonda is an analyst with an average return of -2.8% and a 37.04% success rate. Devarakonda covers the Healthcare sector, focusing on stocks such as Scholar Rock Holding, Nurix Therapeutics, and Incyte.

AbCellera Biologics has an analyst consensus of Strong Buy, with a price target consensus of $8.42, which is an 83.84% upside from current levels. In a report released on August 8, BMO Capital also maintained a Buy rating on the stock with a $7.00 price target.

See today’s best-performing stocks on TipRanks >>

ABCL market cap is currently $1.28B and has a P/E ratio of -8.20.

Read More on ABCL:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).